P A Trail
Overview
Explore the profile of P A Trail including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
410
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Auclair D, Miller D, Yatsula V, Pickett W, Carter C, Chang Y, et al.
Leukemia
. 2007 Jan;
21(3):439-45.
PMID: 17205056
Activating internal tandem duplication (ITD) insertions in the juxtamembrane domain of the FLT3 tyrosine kinase are found in about one fourth of patients with acute myeloid leukemia and have been...
2.
Naglich J, Gupta E, Fargnoli J, Henderson A, Lewin A, Talbott R, et al.
Cancer Res
. 2001 Dec;
61(23):8480-5.
PMID: 11731431
BMS-275291 is an p.o. bioavailable, sulfhydryl-based matrix metalloproteinase (MMP) inhibitor currently in clinical development for the treatment of cancer. This inhibitor was designed to potently inhibit MMP activities while minimally...
3.
Wahl A, Donaldson K, Mixan B, Trail P, Siegall C
Int J Cancer
. 2001 Jul;
93(4):590-600.
PMID: 11477565
The chimeric monoclonal antibody cBR96 conjugated to doxorubicin (cBR96-Dox) is selectively internalized by a wide variety of human carcinomas expressing an extended form of Lewis Y antigen (Le(y)). Endocytosis is...
4.
Salih H, Kosowski S, Haluska V, Starling G, Loo D, Lee F, et al.
J Immunol
. 2000 Aug;
165(5):2903-10.
PMID: 10946324
Members of the TNF superfamily, including Fas, Fas ligand, and CD40, have been shown to be expressed on tumor cells. In the studies described in this work, we report that...
5.
Remsen L, Trail P, Hellstrom I, Hellstrom K, Neuwelt E
Neurosurgery
. 2000 Mar;
46(3):704-9.
PMID: 10719867
Objective: To evaluate dose intensification with osmotic blood-brain barrier disruption (BBBD) and the potential use of drug targeting with monoclonal antibody (MAb) BR96 conjugated to doxorubicin (BR96-DOX, now called SGN15)...
6.
Trail P, WILLNER D, Bianchi A, Henderson A, TrailSmith M, Girit E, et al.
Clin Cancer Res
. 1999 Dec;
5(11):3632-8.
PMID: 10589780
The efficacy of chemotherapy has been improved by regimens that combine several cytotoxic drugs with different mechanisms of action and/or different dose-limiting toxicities. Here we demonstrate clearly, and for the...
7.
Trail P, Bianchi A
Curr Opin Immunol
. 1999 Oct;
11(5):584-8.
PMID: 10508711
Monoclonal antibodies directed to tumor-associated antigens have been chemically conjugated to drugs with different mechanisms of action and different levels of potency. Monoclonal-antibody-directed drug delivery has the potential to both...
8.
KING H, Yurgaitis D, WILLNER D, FIRESTONE R, Yang M, Lasch S, et al.
Bioconjug Chem
. 1999 Mar;
10(2):279-88.
PMID: 10077478
Immunoconjugates of monoclonal antibody BR96 and Doxorubicin have been prepared using a novel series of branched hydrazone linkers. Since each linker bound to the mAb carries two DOX molecules, the...
9.
Ji W, Castellino F, Chang Y, Deford M, Gray H, Villarreal X, et al.
FASEB J
. 1998 Dec;
12(15):1731-8.
PMID: 9837863
Angiogenesis is a complex process that involves endothelial cell proliferation, migration, basement membrane degradation, and neovessel organization. Angiostatin, consisting of four homologous triple-disulfide bridged kringle domains, has previously been shown...
10.
Ji W, Barrientos L, Llinas M, Gray H, Villarreal X, Deford M, et al.
Biochem Biophys Res Commun
. 1998 Jun;
247(2):414-9.
PMID: 9642142
Angiogenesis is a multi-step process that includes endothelial cell proliferation, migration, basement membrane degradation, and new lumen organization. Angiostatin, an internal fragment of plasminogen comprising the first four triple disulfide-linked...